As of 2025-07-11, the Intrinsic Value of WuXi Biologics (Cayman) Inc (2269.HK) is 14.04 HKD. This 2269.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 25.70 HKD, the upside of WuXi Biologics (Cayman) Inc is -45.4%.
The range of the Intrinsic Value is 9.41 - 28.74 HKD.
Based on its market price of 25.70 HKD and our intrinsic valuation, WuXi Biologics (Cayman) Inc (2269.HK) is overvalued by 45.4%.
Range | Selected | Upside | ||
a | ||||
DCF (Growth Exit 5Y) | 9.41 - 28.74 | 14.04 | -45.4% | |
DCF (Growth Exit 10Y) | 26.16 - 85.85 | 40.49 | 57.5% | |
DCF (EBITDA Exit 5Y) | 74.91 - 127.49 | 98.21 | 282.1% | |
Peter Lynch Fair Value | 22.61 - 22.61 | 22.61 | -12.01% | |
P/E Multiples | 17.78 - 24.65 | 22.02 | -14.3% | |
EV/EBITDA Multiples | 25.19 - 39.71 | 31.37 | 22.1% | |
Dividend Discount Model - Stable | 7.38 - 29.1 | 18.24 | -29.0% | |
Dividend Discount Model - Multi Stages | 21.11 - 68.15 | 32.66 | 27.1% |
Market Cap (mil) | 104,470 |
Beta | 2.01 |
Outstanding shares (mil) | 4,065 |
Enterprise Value (mil) | 100,812 |
Market risk premium | 6.5% |
Cost of Equity | 9.7% |
Cost of Debt | 4.25% |
WACC | 9.4% |